patients with scleroderma3 ' and in 15% of patients with systemic lupus erythematosus (SLE). When the prevalence of RP and that of the CTDs is considered one would expect the phenomenon to be secondary only in a minority of the patients. In a previous study, however, we demonstrated a high incidence of secondary disorders in patients referred to an outpatient clinic because of their RP.6 This is probably explained by the selection of more severe cases as we also found that the severity of RP correlated with the extent of systemic involvement in the individual patient.6 Thus the search for an underlying CTD as well as follow up studies are relevant for patients presenting with RP to the clinician. In addition, it would be useful to have tests 634
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Most of the CTDs associated with RP are serologically characterised by the presence of antinuclear antibodies (ANAs) of diverse specificities.7 Some of these specificities are marker antibodies for certain diseases, such as antibodies to a nuclear protein (topoisomerase I or Scl-70/-86) specific for scleroderma,7-"( and anticentromere antibodies, directed against a 19 kilodalton nuclear protein , characteristic for the CRST syndrome (calcinosis, Raynaud's phenomenon, sclerodactyly, telangiectasia). l The recently developed immunoblotting technique allows the detection of more than one of these specificities in a serum sample. 12 The presence of distinct ANAs in the serum of a patient presenting with RP may help in differentiating between primary and secondary RP. In addition, it could have prognostic value for the eventual development of a specific CTD.
In the present report we describe a six year follow up study of 85 patients who were referred to our clinic because of RP. Every two years these patients were screened for clinical and laboratory features of a CTD, and serum samples were stored. We also evaluated the predictive value of ANAs and their specificities (as determined by immunoblotting) for the eventual development of a specific CTD. In the immunoblotting experiments a nuclear protein fraction from HeLa S3 cells was used for the detection of antibodies against Ul-RNP antigens (the 70 kilodalton, A and C proteins associated with U1-snRNA), Sm antigens (the B'/B and D proteins), the SS-B antigen (a 50 kilodalton protein), the Scl-86 antigen, the centromere (CR-19) antigen, and histone.'5 Protein blots containing cytoplasmic HeLa proteins were used for the detection of antibodies against SS-A (a 59 kilodalton protein) and Jo-1. 15 The identity of antigens on immunoblots was established with reference sera from the CDC (see above) and from the laboratories of Dr E Tan (La Jolla, USA), Dr C Bunn (London, UK), Dr R M Bernstein (Manchester, UK), and Dr E Penner (Vienna, Austria). When appropriate, specificity was also tested by RNA immunoprecipitation with antibodies eluted from the antigen band on the blot. '6 Gel electrophoresis and protein blotting were performed as described previously. ' Antibodies against the CR-19 (centromere) antigen were initially present in four of seven patients who developed CRST syndrome during the study period, resulting in a sensitivity of 57%. In addition, these antibodies were present in one patient with sclerodactyly who developed telangiectasia and flexion contractures of the fingers, and in one patient with an initial diagnosis of scleroderma who had not yet developed CRST. In the group of patients without a definite diagnosis of CTD at their initial presentation, the presence of anti-CR-19 had a sensitivity of 60% and a specificity of 98% for the development of CRST.
Antibodies against the SS-A/SS-B antigens, detected equally by counterimmunoelectrophoresis Anti-Ul-RNP antibodies were detected in nine patients with RP by immunoblotting and in seven patients by counterimmunoelectrophoresis. These antibodies were present in five of seven patients with a diagnosis of SLE at follow up, two of them having also developed sclerodermatous changes. In addition, anti-U1-RNP antibodies were present in two patients with, ultimately, a diagnosis of scleroderma, and in two patients with probable scleroderma and undifferentiated CTD at follow up. Anti-Sm antibodies, detected in only one case by counterimmunoelectrophoresis, were detected by immunoblotting in three out of seven patients who, ultimately, fulfilled the criteria for SLE. In two cases anti-Sm antibodies were accompanied by anti-U1-RNP antibodies. Table 2 summarises these data.
COMPARISON OF BI OTTING PROFILES FROM SERA INITIALLY AND AT FOLLOW UP
As mentioned, serum samples were collected and frozen at presentation in 1978 but also every two years when the patients presented for evaluation. We compared the antibody profiles of the samples taken from each individual patient and found that they were remarkably similar. In a few cases minor bands of undefined specificity had disappeared or appeared in the more recent serum sample. Bands of defined identity (Sm, Ul-RNP, SS-B, SS-A, Scl-86, CR-19, and incidentally occurring bands of histone and Jo-1) when present in the follow up serum had been present in all cases already in the 1978 sample (data not shown). This observation indicates that in all patients included in this study the appearance of specific autoantibodies occurred some time before the initial clinical presentation.
Discussion
We describe the six years' clinical follow up of 85 patients who were referred because of their RP. A moderate incidence of underlying disorders (25%Y0), especially scleroderma, was found at their first presentation, as described in our previous report detailing most of the patients involved in the present longitudinal study." In addition, 40%O of the patients had at least one sign or symptom suggestive of CTD, in particular symptoms suggestive of scleroderma. 23 The age of onset of RP was different in our patients with primary RP than in those with one or more symptoms of CTD. Thus the probability of developing CTD appears to increase as the age of onset of RP rises.
Interestingly, most of our patients with a CTD different from scleroderma at the onset of the study also developed sclerodermatous changes during follow up. This is in agreement with the findings that patients with SLE/scleroderma overlap syndromes present with SLE-like symptoms and progress to a more scleroderma-like syndrome.)4
We also evaluated the predictive value of ANAs for the development of a CTD. We used not only the conventional indirect immunofluorescence technique on human fibroblasts, but also immunoblotting on HeLa cell proteins. The latter technique allows the detection of more than one antigenic specificity in a serum sample. Thus we detected antibodies against Scl-86 in two sera with, in addition, anti-U l-RNP antibodies. We showed that the presence of ANAs was associated with the development of additional signs or symptoms of CTD in patients with none or only one svmptom at their first presentation. This association was present only when ANAs were detected by immunoblotting.
When ANAs were considered positive only in the presence of antibodies against proteins of defined specificity, a stronger association was found. Apparently, by identifying specific antigenic determinants the immunoblotting technique is sensitive group.bmj.com on November 7, 2017 -Published by http://ard.bmj.com/ Downloaded from and specific for the detection of evolving connective tissue diseaes.
The immunoblotting technique proved to be useful for the detection of antibodies associated with scleroderma-namely, antibodies against the Scl-86 and the CR-19 antigen. Anti-Scl-86 antibodies were highly specific for the presence or future development of scleroderma as has been described earlier.8
The predictive power of anti-CR-19 with respect to the future development of CRST, including calcinosis, was also apparent from our study: calcinosis was present in none of the patients at the onset of the study but developed later on in four of six patients with anti-CR-19 at their first presentation. Our data on the diagnostic sensitivity and specificity of antiScl-86 and anti-CR-19 are in agreement with those of other studies.2927
Antibodies to U1-RNP, originally described as a prerequisite for the diagnosis of an SLE/ scleroderma overlap syndrome designated as mixed connective tissue disease,28 were indeed indicative of the development of SLE/scleroderma overlap, though these antibodies were also present in the sera of some patients with scleroderma lacking SLE-like characteristics.
We observed that antibody specificities in the sera of the patients hardly changed during a six year period. Specificities characteristic for clinical disease entities were already detectable at the start of the study. Thus the presence of antibodies against Scl-86, CR-19, SS-A/SS-B, or Ul-RNP has prognostic value for specific diagnoses.
In conclusion, a slowly progressive CTD, in most cases scleroderma, can be diagnosed in many patients who present at an outpatient clinic because of severe Raynaud's phenomenon. In patients presenting with primary RP the presence of ANAs, as detected by immunoblotting, has discriminative power for the future development of connective tissue diseases. The antigenic specificities of the antinuclear antibodies are indicative of the clinical entity that will develop, whether scleroderma, CRST syndrome, or other connective tissue diseases. 
